Adding VYRE Network (CAPV) to the Watch List.
Look What We Found. Our First Internet Play in Ages, And It's a Doozy.
We would categorize this...
OMNIQ (OMQS) Graduates to NASDAQ. And Three Wall Street Research Reports Follow.
Wall Street Brokerage Price Target Estimates of $15 - $18 Per Share.
Without disrupting legacy sales - CEO Shai...
Report: Ehave Inc (EHVVF) Our Favorite Psychedelic Company
WE LOOKED FAR AND WIDE TO FIND OUR FAVORITE
What exactly is a favorite?
First...
Citius Pharma (CTXR) $2.15. Price Target of $8.00 Maintained, Post Safety and Efficacy Review.
Investment Banker Buy Rating Maintained: DSMB Gives the Thumbs Up – Data in Early 2022.
CITIUS NEWS ARCHIVE
Up 191%, HealthLynked (HLYK) Reporting Decent Numbers.
Up as much as 417% from where we added it to the Watch List, the Company continues to report increasing revenues while...
Bitcoin $30,000. Time to Bargain Hunt? Read This First.
The Bit Short: Inside Crypto’s Doomsday Machine
Scary article on Tether/Bitcoin posted on...
Meet Draganfly (DFLYF) the Tesla of Drones.
A New Leader In The Drone Industry Emerges
US Government Bans Chinese Drones
Surprise...
Report: My-Cam™ and My-Cardia™ the Ultimate ‘Any-Doctor-Anywhere’ Telehealth Monitoring Application.
New and Updated Report on CB Scientific (CBSC) $1.05.
Revolutionary Any-Doctor-Any Where, at Home Heart Rate Monitor, can...
Lantern Pharma (LTRN) $21.25 and Provention Bio (PRVB) $13.51 Added to Biotech Six Pack.
The 2021 Biotech Six Pack: Stocks We Expect to Double!
These are ideas #3 and #4 for the 'Biotech...
Adding Citius Pharma (CTXR) $1.29 to the 2021 Biotech Portfolio.
The 2021 Biotech Six Pack, Six Stocks We Expect to Double.
We're still putting the 2021 list together now,...